Identification of compounds that selectively target highly chemotherapy refractory neuroblastoma cancer stem cells
Abstract:
Relapse of cancer months or years after an apparently successful therapy is probably caused by cancer stem cells (CSCs) due to their intrinsic features like dormant periods, radiorefraction, and acquired multidrug resistance (MDR) phenotypes, among other mechanisms of cellular drug evasiveness. Thus, the lack of currently efficacious interventions remains a major problem in the treatment of malignancies, together with the inability of existing drugs to destroy specifically CSCs. Neuroblastomas per se are highly chemotherapy-refractory extracranial tumors in infants with very low survival rates. So far, no effective cytostatics against this kind of tumors are clinically available. Therefore, we have put much effort into the development of agents to efficiently combat this malignancy. For this purpose, we tested several compounds isolated from Cuban propolis on induced CSCs (iCSC) derived from LAN-1 neuroblastoma cells which expressed several characteristics of tumor-initiating cells both in in-vitro and in-vivo models. Some small molecules such as flavonoids and polycyclic polyprenylated acylphloroglucinols (PPAP) were isolated using successive RT-HPLC cycles and identified employing mass spectrometry and NMR spectroscopic techniques. Their cytotoxicity was first screened in sensitive cell systems by MTT proliferation assays and afterwards studied in less sensitive neuroblastoma iCSC models. We found several compounds with considerable anti-iCSC activity, most of them belonging to the PPAP class. The majority of the compounds act in a pleiotropic manner on the molecular biology of tumors although their specific targets remain unclear. Nevertheless, two substances, one of them a flavonoid, induced a strong disruption of tubulin polymerization. In addition, an unknown compound strongly inhibited replicative enzymes like toposimerases I/II and DNA polymerase. Here, we report for the first time cytotoxic activities of small molecules isolated from Caribbean propolis which could be promising therapeutics or lead structures against therapy-refractory neuroblastoma entities. *Contributed equally.
Insights
Cuban propolis compounds show promise against therapy-resistant neuroblastoma cancer stem cells (CSCs). These natural molecules, particularly PPAPs, exhibit significant anti-CSC activity, offering potential new treatments for this challenging infant cancer.
Area of Science:
- Natural Product Chemistry
- Cancer Biology
- Pharmacology
Background:
- Cancer stem cells (CSCs) drive relapse due to resistance mechanisms like dormancy and multidrug resistance (MDR).
- Neuroblastomas are aggressive infant tumors with poor survival rates and limited effective chemotherapy options.
- Existing treatments struggle to specifically target and eliminate CSCs, necessitating novel therapeutic strategies.
Purpose of the Study:
- To investigate the potential of small molecules from Cuban propolis as anti-cancer agents against neuroblastoma cancer stem cells (CSCs).
- To identify specific compounds with cytotoxic activity against therapy-refractory neuroblastoma-derived CSCs (iCSCs).
- To explore the mechanisms of action of these propolis-derived compounds.
Main Methods:
- Isolation and identification of compounds from Cuban propolis using RT-HPLC, mass spectrometry, and NMR.
- Generation of induced CSCs (iCSCs) from LAN-1 neuroblastoma cells.
- Cytotoxicity screening using MTT assays in sensitive cell lines and neuroblastoma iCSC models.
Main Results:
- Several compounds, predominantly polycyclic polyprenylated acylphloroglucinols (PPAPs), demonstrated significant anti-iCSC activity.
- Two compounds, including a flavonoid, were found to disrupt tubulin polymerization.
- An unidentified compound strongly inhibited topoisomerases I/II and DNA polymerase.
Conclusions:
- Small molecules isolated from Caribbean propolis exhibit promising cytotoxic activity against neuroblastoma CSCs.
- These compounds, particularly PPAPs, represent potential therapeutic leads or drug candidates for treating chemotherapy-refractory neuroblastomas.
- Further research into their specific molecular targets and mechanisms is warranted.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...


